Separately, BTIG Research lowered shares of OncoSec Medical from a buy rating to a neutral rating in a report on Monday, November 14th.
OncoSec Medical Price Performance
Shares of ONCS opened at $3.73 on Monday. OncoSec Medical has a one year low of $3.35 and a one year high of $34.76. The company has a 50-day simple moving average of $10.55 and a two-hundred day simple moving average of $14.49. The firm has a market capitalization of $6.68 million, a PE ratio of -0.18 and a beta of 1.79.
Institutional Investors Weigh In On OncoSec Medical
About OncoSec Medical
OncoSec Medical Incorporated, a late-stage immuno-oncology company, focuses on designing, developing, commercializing intra-tumoral DNA-based therapeutics to stimulate and augment anti-tumor immune responses for the treatment of cancer. The company's product pipeline includes KEYNOTE-695, which is in Phase 2 trial for the treatment of advanced melanoma; TAVO + SARS-CoV-2 spike glycoprotein, which is in Phase 1 clinical trial for the treatment of COVID-19; and TAVO + epacadostat + pembrolizumab, which is in Phase 1 clinical trial for the treatment of squamous cell carcinoma head and neck cancer.
- Get a free copy of the StockNews.com research report on OncoSec Medical (ONCS)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Three CBD Stocks to Dominate a Budding Industry
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.